Oncogenic Osteomalacia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Benign Fibro-Osseous Lesions Plus…
“Vision is the art of seeing things invisible.” Jonathan Swift 1667 - 1745 Benign Fibro-osseous Lesions Plus… Steven R. Singer, DDS [email protected] 212.305.5674 Benign Fibro-osseous Lesions Fibrous Dysplasia A group of lesions in which normal bone is Localized change in bone metabolism replaced initially by fibrous connective tissue Normal cancellous bone is replaced by Over time, the lesion is infiltrated by osteoid fibrous connective tissue and cementoid tissue The connective tissue contains varying amounts of abnormal bone with irregular This is a benign and idiopathic process trabeculae Trabeculae are randomly oriented. (Remember that normal trabeculae are aligned to respond to stress) Fibrous Dysplasia Fibrous Dysplasia Lesions may be solitary (monostotic) or Fibrous dysplasia is non-hereditary involve more than one bone (polyostotic) Caused by a mutation in a somatic cell. Monostotic form accounts for 70% of all Extent of lesions depends on the timing of cases the mutation. Polyostotic form is more common in the first If the mutation occurs earlier, the disease decade will be more widespread throughout the M=F except in McCune-Albright syndrome, body. An example is McCune-Albright which is almost exclusively found in females Syndrome 1 Fibrous Dysplasia Fibrous Dysplasia McCune-Albright Syndrome • Monostotic and polyostotic forms usually -Almost exclusively begins in the second decade of life females -Polyostotic fibrous • Slow, painless expansion of the jaws dysplasia • Patients may complain of swelling or have -
Effects of Tumor-Induced Osteomalacia on the Bone Mineralization Process
Calcif Tissue Int (2009) 84:313–323 DOI 10.1007/s00223-009-9216-z Effects of Tumor-Induced Osteomalacia on the Bone Mineralization Process K. Nawrot-Wawrzyniak Æ F. Varga Æ A. Nader Æ P. Roschger Æ S. Sieghart Æ E. Zwettler Æ K. M. Roetzer Æ S. Lang Æ R. Weinkamer Æ K. Klaushofer Æ N. Fratzl-Zelman Received: 24 October 2008 / Accepted: 4 January 2009 / Published online: 14 February 2009 Ó The Author(s) 2009. This article is published with open access at Springerlink.com Abstract Fibroblast growth factor 23 (FGF23) overex- distribution using quantitative backscattered electron pression has been identified as a causative factor for tumor- imaging were performed on the bone biopsy. The data induced osteomalacia (TIO) characterized by hypophos- showed important surface osteoidosis and a slightly phatemia due to increased renal phosphate wasting, low increased osteoblast but markedly decreased osteoclast 1,25(OH)2D3 serum levels, and low bone density. The number. The mineralized bone volume (-11%) and miner- effects of long-lasting disturbed phosphate homeostasis on alized trabecular thickness (-18%) were low. The mean bone mineralization are still not well understood. We report degree of mineralization of the bone matrix (-7%), the most on a patient with a 12-year history of TIO, treated with frequent calcium concentration (-4.1%), and the amounts of 1,25(OH)2D3 and phosphate, who finally developed hyper- fully mineralized bone (-40.3%) were distinctly decreased, parathyroidism with gland hyperplasia before the tumor while the heterogeneity of mineralization (?44.5%) and the could be localized in the scapula and removed. -
Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia
Open Access Case Report DOI: 10.7759/cureus.15507 Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia Eluwana A. Amaratunga 1 , Emily B. Ernst 1 , James Kamau 1 , Ragarupa Kotala 1 , Richard Snyder 1 1. Internal Medicine, St. Luke’s University Health Network, Easton, USA Corresponding author: Eluwana A. Amaratunga, [email protected] Abstract Osteomalacia is a widely prevalent bone disorder that is caused by an imbalance in body calcium and phosphate. Tumor-induced osteomalacia (TIO) is a rare form of osteomalacia that is associated with mesenchymal tumors. It is caused by overproduction of fibroblast growth factor 23 (FGF-23), a hormone involved in phosphate regulation. A 59-year-old male with a history of factor V Leiden mutation, pulmonary embolism, and deep vein thrombosis was diagnosed with oncogenic osteomalacia in 2008 following laboratory findings significant for low phosphorus and elevated FGF-23 levels. He underwent a resection of a right suprascapular notch mass with the biopsy confirming a phosphaturic mesenchymal tumor. He was maintained on oral phosphorus and calcitriol replacements with a regular follow-up with oncology and nephrology. Eight years later, the patient’s phosphorus levels started declining despite replacement. A repeat test showed FGF-23 levels once again elevated. A whole-body magnetic resonance imaging (MRI) scan showed no significant findings. The patient was continued on oral replacement therapy with a close follow-up. Two years later, urine phosphorus excretion was elevated at 2494 mg per 24 hours with low plasma phosphorus (1.2 mg/dL) and an elevated FGF-23 level of 1005 relative units (RU)/mL. -
Rickets and Osteomalacia Management )
Rule Category: Medical ` Ref: No: 2013-MN-0010 Version Control: Version No.3.0 Effective Date: 08-02-2019 Revision Date: February 2020 Rickets and Osteomalacia Management ) Adjudication Guideline Table of content Abstract Scope Adjudication Policy Denial codes Appendices Page 1 Page 2 Page 2 Page 3 Page 3 Approved by: Daman Abstract Responsible: Medical Standards & Research For Members Related Adjudication Guidelines: None Rickets and Osteomalacia are the two disorder caused by insufficient level of vitamins D in the body. When vitamin D deficiency occurs in children is termed as rickets, whereas deficient mineralization of the growth plate in adult termed Disclaimer Osteomalacia. By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: Rickets symptoms aches, bone pain, and sometimes enlargement occurs in The information contained in this Adjudication Guideline is intended to outline the procedures of bones at joints, such as the wrists. Fracture may occur without any known adjudication of medical claims as applied by the trauma. National Health Insurance Company – Daman PJSC (hereinafter “Daman”). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be In Osteomalacia bone pain and muscle weakness are the classical symptoms. used for the purpose of reference or guidance for adjudication procedures and shall not be construed Fractures may also take place with little or no recognized trauma. as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted Causes of Rickets and Osteomalacia can be lack of vitamins D intake or less through Daman Adjudication Guideline. -
Orthopedic-Conditions-Treated.Pdf
Orthopedic and Orthopedic Surgery Conditions Treated Accessory navicular bone Achondroplasia ACL injury Acromioclavicular (AC) joint Acromioclavicular (AC) joint Adamantinoma arthritis sprain Aneurysmal bone cyst Angiosarcoma Ankle arthritis Apophysitis Arthrogryposis Aseptic necrosis Askin tumor Avascular necrosis Benign bone tumor Biceps tear Biceps tendinitis Blount’s disease Bone cancer Bone metastasis Bowlegged deformity Brachial plexus injury Brittle bone disease Broken ankle/broken foot Broken arm Broken collarbone Broken leg Broken wrist/broken hand Bunions Carpal tunnel syndrome Cavovarus foot deformity Cavus foot Cerebral palsy Cervical myelopathy Cervical radiculopathy Charcot-Marie-Tooth disease Chondrosarcoma Chordoma Chronic regional multifocal osteomyelitis Clubfoot Congenital hand deformities Congenital myasthenic syndromes Congenital pseudoarthrosis Contractures Desmoid tumors Discoid meniscus Dislocated elbow Dislocated shoulder Dislocation Dislocation – hip Dislocation – knee Dupuytren's contracture Early-onset scoliosis Ehlers-Danlos syndrome Elbow fracture Elbow impingement Elbow instability Elbow loose body Eosinophilic granuloma Epiphyseal dysplasia Ewing sarcoma Extra finger/toes Failed total hip replacement Failed total knee replacement Femoral nonunion Fibrosarcoma Fibrous dysplasia Fibular hemimelia Flatfeet Foot deformities Foot injuries Ganglion cyst Genu valgum Genu varum Giant cell tumor Golfer's elbow Gorham’s disease Growth plate arrest Growth plate fractures Hammertoe and mallet toe Heel cord contracture -
Oncogenic Osteomalacia
ONCOGENIC_Martini 14/06/2006 10.27 Pagina 76 Case report Oncogenic osteomalacia Giuseppe Martini choice; if the tumour cannot be found or if the tumour is unre- Fabrizio Valleggi sectable for its location, chronic administration of phosphate Luigi Gennari and calcitriol is indicated. Daniela Merlotti KEY WORDS: oncogenic osteomalacia, hypophosphoremia, fractures, oc- Vincenzo De Paola treotide scintigraphy. Roberto Valenti Ranuccio Nuti Introduction Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy Osteomalacia is a metabolic bone disorder characterized by reduced mineralization and increase in osteoid thickness. Address for correspondence: This disorder typically occurs in adults, due to different condi- Prof. Giuseppe Martini tions impairing matrix mineralization. Its major symptoms are Dipartimento di Medicina Interna e Malattie Metaboliche diffuse bone pain, muscle weakness and bone fractures with Azienda Ospedaliera Senese minimal trauma. When occurs in children, it is associated with Policlinico “S. Maria alle Scotte” a failure or delay in the mineralization of endochondral new Viale Bracci 7, 53100 Siena, Italy bone formation at the growth plates, causing gait distur- Ph. 0577586452 bances, growth retardation, and skeletal deformities, and it is Fax 0577233446 called rickets. E-mail: [email protected] Histologically patients with osteomalacia present an abun- dance of unmineralized matrix, sometimes to the extent that whole trabeculae appeared to be composed of only osteoid -
Oncogenic Osteomalacia
ONCOGENIC OSTEOMALACIA THE SEARCH, THE TREATMENT, AND THE CURE OF A DEBILITATING TUMOR NEW ENGLAND AACE ANNUAL MEETING October 14, 2017 Christopher W. Lee, MD, Endocrinology Fellow Boston University School of Medicine Boston Medical Center Department of Medicine Section of Endocrinology, Diabetes, Nutrition and Weight Management Disclosures • No financial or other conflicts of interest to disclose Objectives • Recognize the clinical features of patients with oncogenic osteomalacia • Describe the role of FGF23 in the pathophysiology of the disease • Understand an algorithmic approach to diagnosis and treatment of oncogenic osteomalacia Case Presentation • 48 year-old Haitian man presented to the hospital with several months of increasing lower back pain, debilitating fatigue, and progressive weakness of all four extremities • Acetaminophen, gabapentin, muscle relaxants provided no relief • Physical therapy provided mild relief • Denied any glucocorticoid use in the past • Review of Systems: • Endorsed diffuse joint and bone pains • No fevers, chills, headaches, hearing difficulties, weight loss, change in libido, or history of kidney stones Case Presentation • PMH: • Allergies: • L1-L3 laminectomy in Haiti 3 • None years prior (for unclear reasons) • Family History: • Post-surgery, he had initially been dependent on crutches • No thyroid disease, and has had progressive autoimmune disorders, or muscle weakness to the point disorders of bone metabolism he is now wheelchair dependent • Social History: • Medications: • Single • Non-smoker • Acetaminophen prn • No children • Cyclobenzaprine prn Physical Exam • Vital Signs: Afebrile, BP 129/76, HR 71, Wt 135 lbs, BMI 23. • General: Sitting in wheelchair. NAD. A&Ox3. • HEENT: EOMI. PERRL. No stare or lid lag. MMM. Temporal wasting. • Thyroid: Normal size, soft, non-tender. -
Musculoskeletal Radiology
MUSCULOSKELETAL RADIOLOGY Developed by The Education Committee of the American Society of Musculoskeletal Radiology 1997-1998 Charles S. Resnik, M.D. (Co-chair) Arthur A. De Smet, M.D. (Co-chair) Felix S. Chew, M.D., Ed.M. Mary Kathol, M.D. Mark Kransdorf, M.D., Lynne S. Steinbach, M.D. INTRODUCTION The following curriculum guide comprises a list of subjects which are important to a thorough understanding of disorders that affect the musculoskeletal system. It does not include every musculoskeletal condition, yet it is comprehensive enough to fulfill three basic requirements: 1.to provide practicing radiologists with the fundamentals needed to be valuable consultants to orthopedic surgeons, rheumatologists, and other referring physicians, 2.to provide radiology residency program directors with a guide to subjects that should be covered in a four year teaching curriculum, and 3.to serve as a “study guide” for diagnostic radiology residents. To that end, much of the material has been divided into “basic” and “advanced” categories. Basic material includes fundamental information that radiology residents should be able to learn, while advanced material includes information that musculoskeletal radiologists might expect to master. It is acknowledged that this division is somewhat arbitrary. It is the authors’ hope that each user of this guide will gain an appreciation for the information that is needed for the successful practice of musculoskeletal radiology. I. Aspects of Basic Science Related to Bone A. Histogenesis of developing bone 1. Intramembranous ossification 2. Endochondral ossification 3. Remodeling B. Bone anatomy 1. Cellular constituents a. Osteoblasts b. Osteoclasts 2. Non cellular constituents a. -
Intramuscular Myxoma Associated with Fibrous Dysplasia
Mazabraud’s Syndrome: Intramuscular Myxoma Associated with Fibrous Dysplasia Authors: Dr Fevziye Kabukcuoglu and Dr Yavuz Kabukcuoglu Creation date: January 2005 Scientific Editor: Prof Loic Guillevin Department of Pathology and Department of Orthopedics and Traumatology. Sisli Etfal Training and Research Hospital, Istanbul Turkey. [email protected] Abstract Key words Definition and disease name Differential Diagnosis Incidence Etiology Clinical Description Radiologic findings Histopathology Treatment Unresolved Questions References Abstract Mazabraud’s syndrome is a rare disease known as the association of intramuscular myxoma with fibrous dysplasia. The number of reported cases in 2004 is 55. Myxomas generally occur as multiple masses and fibrous dysplasia most commonly appear with its polyostotic form. Both lesions tend to involve the same anatomical region. Patients usually present with a painless mass with a history of long duration due top lack of symptoms. Most fibrous dysplasias are asymptomatic while some may appear with pain, skeletal deformities or fractures. Generally fibrous dysplasias occur during the growth period and the myxomas appear during adult life. The relationship between fibrous dysplasia and myxoma remains unclear, where an underlying localized error in tissue metabolism has been proposed. Molecular genetic analysis has shown activating mutations in GNAS1 gene. Several benign lesions as well as richly myxoid malignant lesions may be confused with myxoma. Histopathologic examination should be carried out to exclude malignancy. Treatment is dependent on the extent of the lesions. Malignant transformation of myxoma is not reported, although local recurrence may be expected if incompletely resected. While sarcomatous transformation is uncommon for fibrous dysplasia, greater risk has been reported for Mazabraud’s syndrome. -
(12) United States Patent (10) Patent No.: US 7,981,419 B2 Yamashita Et Al
US007981419B2 (12) United States Patent (10) Patent No.: US 7,981,419 B2 Yamashita et al. (45) Date of Patent: Jul. 19, 2011 (54) METHOD FOR TREATING EP 0314161 A1 10/1988 HYPOPHOSPHATEMICUSING FGF-23 ANTIBODY BONE DISEASES g;JP 561478926 :1 11/1986 JP H-02-117920 2/1990 (75) Inventors: Takeyoshi Yamashita, Tokyo (JP); W0 WO 99/60017 11/1999 TakashiSatoru Mizutani, Shimada, Yokohama Brookline, (JP); MA Seiji(US); $8W0 $8WO 00/73454 AlA1 120000 Fukumoto, Tokyo (JP) W0 WO 01/40466 A2 6/2001 W0 WO 01/42451 A2 6/2001 (73) Assignee: KyoWa Hakko Kirin Co., Ltd., Tokyo W0 WO 01/49740 A1 7/2001 (JP) W0 WO 01/60850 A1 8/2001 W0 WO 01/61007 A2 8/2001 ( * ) Notice: patentSubject' 1s to extendedany disclaimer, or adjusted the term under of this 35 W0 WO 02/08271 A1 1/2002 U.S.C. 154(1)) by 173 days. W0 WO 02/14504 A1 2/2002 W0 WO 02/76467 A1 3/2002 . W0 W0 02/088358 A2 11/2002 (21) Appl' No" 1262551 W0 W0 03/057733 A1 1/2003 . W0 WO 02/43478 5/2004 (22) Flledi Dec-1, 2008 W0 WO 2006/078072 A1 7/2006 WO WO-2008/057683 A2 5/2008 (65) Prior Publication Data W0 WO 2008/092019 A1 7/2008 US 2009/0110677 A1 Apr. 30, 2009 OTHER PUBLICATIONS Notice of Allowance for Korean Patent Application 10-2003 Related US. Application Data 7001931 Dated Nov. 26, 2008. (63) Continuation of application No. 10/344,339, ?led as Kenneth E. -
Bone Scan in Tumor-Induced Osteomalacia
Bone Scan in Tumor-Induced Osteomalacia Hee K. Lee, Wei Wen Sung, Paul Solodnik and Mona Shimshi Section of Nuclear Medicine, Department of Medicine and Department of Radiology, Mount Sinai School of Medicine and Elmhurst Hospital Center, Elmhurst, New York revealed markedly improved focal lesions while diffusely in A 66-yr-old female was admitted with a 3-yr history of general creased activity, especially in the skull remained (Fig. 2). ized bone pain and nasal obstruction. CT and MRI of the head revealed a large nasal mass. A whole-body bone scan revealed multifocal lesions of increased activity. Surgical removal of the DISCUSSION nasal tumor revealed hemangiopericytoma. The patient im Tumor-induced osteomalacia or oncogenic osteomalacia proved clinically and a repeat bone scan 10 mo after surgery is a rare phenomenon with less than 100 reported cases in revealed markedly improved findings. the literature. Most of the tumors are benign, mesenchymal Key Words: oncogenous;osteomalacia;bone scan in origin and highly vascular (1,2). Benign tumors associ ated with osteomalacia include giant-cell granuloma, J NucÃMed 1995; 36:247-249 cavernous hemangioma, nonossifying fibroma, benign ossifying mesenchymal tumors, fibrous xanthoma, heman giopericytoma, angiosarcoma, osteoblastoma and fibroan- 'ncogenous osteomalacia is a rarely described clinical gioma. Malignant tumors associated with oncogenic osteo o, malacia are extremely rare with less than 10reported cases entity that may mimic metastatic bone lesions in bone (3). There is one reported case each of prostate cancer (4) scanning. It is most commonly associated with benign tu and oat-cell lung cancer (5). More common are the malig mors of mesenchymal origin and can be cured after surgical nant soft-tissue sarcomas and malignant neurinoma. -
Oncogenic Hypophosphatemic Osteomalacia Principal Discussant: ZALMAN S
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 24 (1983), pp. 113—123 NEPHROLOGY FORUM Oncogenic hypophosphatemic osteomalacia Principal discussant: ZALMAN S. AGUS University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania muscle weakness and subsequently was treated with I rg/day of I aOH Editors vitamin D and 3 g/day of elemental phosphorus. On this regimen, the serum phosphate varied between 1.8 and 2.1 mg/dl, the serum calcium JORDANJ.COHEN level ranged between 8.2 and 8.6 mg/dl, and the PTH increased from 9 JOHN T.HARRINGION to 12 tlEq/ml. Treatment with calcium carbonate was reinstituted, but JEROME P. KASSIRER after 6 months of therapy the patient was readmitted for evaluation NICOLAOS E. MADIAS because of continuing bone pain. On admission, she complained of new discomfort and pressure in the left plantar area. The blood pressure was 140/86 mm Hg; pulse, 72; and Managing Editor weight, 186 lbs. Funduscopic examination showed minimal arteriolar CHERYL J. ZUSMAN narrowing, sharp discs, and no hemorrhages or exudates. The rib cage was diffusely tender to palpation. Examination of the heart and lungs MichaelReese Hospital and Medical Center was normal. Neither hepatosplenomegaly nor costovertebral angle tenderness was present. There was a firm, slightly tender, small nodule University of Chicago Pritzker School of Medicine barely palpable in the sole of the left foot. and The BUN was 12 mg/dl and the serum creatinine was 1.1 mg/dl. New EnglandMedical Center Blood chemistry studies revealed: sodium, 136 mEq/liter; potassium, Tufts University School of Medicine 3.6, mEq/liter; chloride, 104 mEq/liter; and bicarbonate, 27 mEq/liter.